Danaher Corporation (DHR)
NYSE: DHR · Real-Time Price · USD
189.73
-5.09 (-2.61%)
At close: May 9, 2025, 4:00 PM
189.73
0.00 (0.00%)
After-hours: May 9, 2025, 4:03 PM EDT
Danaher Revenue
Danaher had revenue of $5.74B in the quarter ending March 28, 2025, a decrease of -0.95%. This brings the company's revenue in the last twelve months to $23.82B, up 0.35% year-over-year. In the year 2024, Danaher had annual revenue of $23.88B, down -0.06%.
Revenue (ttm)
$23.82B
Revenue Growth
+0.35%
P/S Ratio
5.93
Revenue / Employee
$378,095
Employees
63,000
Market Cap
135.78B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 23.88B | -15.00M | -0.06% |
Dec 31, 2023 | 23.89B | -2.75B | -10.33% |
Dec 31, 2022 | 26.64B | 1.84B | 7.42% |
Dec 31, 2021 | 24.80B | 2.52B | 11.30% |
Dec 31, 2020 | 22.28B | 4.37B | 24.42% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
DHR News
- 2 days ago - Danaher to Present at Bank of America Securities Healthcare Conference - PRNewsWire
- 3 days ago - Danaher Announces Quarterly Dividend - PRNewsWire
- 3 days ago - Danaher: A Capital Intensive Business Offering Low Risk, Low Reward Opportunity - Seeking Alpha
- 7 days ago - Danaher: Q1 Beat Fails To Trigger Guidance Upgrade - Seeking Alpha
- 10 days ago - Baron Health Care Fund Q1 2025 Top Contributors And Detractors - Seeking Alpha
- 10 days ago - Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow - PRNewsWire
- 17 days ago - Danaher Corporation (DHR) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 17 days ago - Danaher Beats Q1 Expectations, Signals Caution Ahead In 'Unusual Times' - Benzinga